
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 20, 2026, 4:31 PM ET
BioCardia received a Nasdaq notice that its stockholders' equity of $835,000 is below the $2.5 million minimum, with a plan due January 4, 2027.
Nasdaq: $BCDACardiovascular cell therapyClinical stageGoing-concern riskDilution risk
BCDA Stock Hub: BioCardia News, CardiAMP and Helix
BioCardia is closer to submitting CardiAMP for review in Japan and is pursuing a separate U.S. pathway for its Helix catheter. Its first randomized CardiAMP heart failure trial missed its primary endpoint, and the follow-up study faces a shorter financial runway than its clinical timetable. With $2.224 million in September cash and no capacity under the existing at-the-market prospectus supplement at the November filing, the central question is whether BioCardia can fund the work needed to turn regulatory progress into usable clinical and commercial evidence. November 12 Form 10-Q. Nasdaq issued a notice on November 20 over BioCardia’s stockholders’ equity. November 20 Form 8-K.
Full research report · PDF
BioCardia ($BCDA) research report, November 20, 2026
21 pages on CardiAMP, Helix, earnings, cash runway, dilution, Nasdaq status and clinical evidence. For personal use only: redistribution prohibited.
Next catalyst
Helix FDA pre-submission feedback · fourth quarter of 2026 target
No exact date has been announced. The company’s November 12 milestone list gives the fourth quarter for a pre-submission meeting, while its Helix update allows feedback or a meeting. The Japanese CardiAMP filing has a wider window, extending into the first quarter of 2027. November 12 company milestone list.
Completed: BioCardia announced the end of its Japan consultation on November 6 and reported quarterly results on November 12. Consultation release · Quarterly results
BCDA stock at a glance
Chart analysis · JC
Technical chart analysis of $BCDA with bull and bear scenarios on JC Just Charts.
Where BioCardia stands now
BioCardia’s two nearer regulatory opportunities have become more concrete without removing the funding constraint. Japan’s completed consultation puts the company closer to delivering a marketing application. The acceptance of the revised U.S. pre-submission for Helix opens a feedback step on a device that might have uses beyond CardiAMP. In both cases the progress is in preparation and communication with regulators. The next distinction is between announced work and a submission or decision that the agency can act on. November 6 Japan release · October 19 Helix release.
The runway is shorter than the clinical follow-up. The November filing says September cash is insufficient beyond January 2027 under the current operating plan without additional funding. The confirmatory trial needs patient enrollment and then clinical follow-up. A regulatory filing, even if timely, cannot by itself finance that interval. Form 10-Q, Future Funding Requirements · HF II study record.
The constructive case
Japan and U.S. device work could attract partners with different interests. A partner paying for defined commercial or development rights could fund a program without issuing common shares. An independent Helix authorization could also separate part of the opportunity from the outcome of a single cell therapy trial.
The cautious case
The existing equity channel is exhausted under its supplement, the lead study missed its primary endpoint, and cash is needed well before the next trial can provide its answer. A deal may come with substantial dilution or transfer of rights, even if both regulatory tracks make progress.
Latest BioCardia news
Nov 20, 2026
BioCardia receives Nasdaq notice on stockholders' equity requirement
BioCardia received a Nasdaq notice that its stockholders' equity of $835,000 as of September 30, 2026 is below the $2.5 million minimum for the Nasdaq Capital Market. The company has until January 4, 2027 to submit a plan to regain compliance, which if accepted could bring an extension of up to 180 calendar days from November 20, 2026. The notice has no immediate effect, and the stock continues trading under BCDA. The company intends to submit a plan.
Nov 6, 2026
BioCardia completes PMDA clinical consultation for CardiAMP Cell Therapy System
On November 6, 2026, BioCardia announced completion of its clinical consultation process with Japan's PMDA for the CardiAMP Cell Therapy System. The company is advancing toward submission of a marketing approval application. The press release was furnished to the SEC as Exhibit 99.1 to a Form 8-K.
Oct 19, 2026
FDA accepts the revised Helix pre-submission
BioCardia expects written FDA feedback and a subsequent meeting during Q4. The accepted package requests agency feedback on a potential De Novo route; it is not marketing clearance.
Oct 7, 2026
CardiAMP HF II design poster scheduled at HFSA
The announcement scheduled a design and scientific-rationale poster for the October 9–12 meeting. It did not disclose a new efficacy readout. The company reiterated that the ongoing study may support a premarket application.
Oct 1, 2026
Revised Helix feedback package completed
The revised Q-Submission incorporated prior FDA advice. Completion of this preparatory step is distinct from a final marketing application or authorization.
Sep 23, 2026
Japan Shonin submission targeted for Q4
BioCardia described work on the Shonin application, quality-management application and foreign-manufacturer registration. Possible Q4 2027 clearance is conditional on a successful submission and review. CardiAMP HF II was enrolling at four U.S. centers.
BCDA stock catalysts: the dated calendar
- September 21, 2026 — Nasdaq notified BioCardia that the August bid-price matter was resolved. Completed · Form 8-K
- October 19, 2026 — BioCardia announced FDA acceptance of the revised Helix pre-submission package. Completed · company announcement
- November 6, 2026 — BioCardia announced completion of the PMDA consultation on CardiAMP application materials. Completed · Exhibit 99.1
- November 12, 2026 — September-quarter results and 10-Q. Reported · results release
- Fourth quarter of 2026 — Helix De Novo pre-submission meeting or feedback. Company expectation, no fixed day · November 12 milestones
- Fourth quarter of 2026 or first quarter of 2027 — CardiAMP Shonin submission in Japan. Company target · November 12 milestones
- January 4, 2027 — Deadline for BioCardia to submit a plan to regain compliance with Nasdaq’s minimum stockholders’ equity rule. Nasdaq deadline for plan submission · November 20 Form 8-K
- First quarter of 2027 — Original CardiAMP HF manuscript; full Helix De Novo request; Heart3D submission and a partner study using Helix and Heart3D. Company targets · November 12 milestones and Helix update
Clinical programs and devices at different stages
RECRUITING
CardiAMP HF II
Randomized confirmatory trial in a selected population with ischemic heart failure and reduced ejection fraction. Study record · Endpoints and design
ACTIVE, NOT RECRUITING
CardiAMP in refractory angina
The study record covers the open-label roll-in and the randomized phase; the May findings came from the roll-in. Study record · Clinical context
FUNDING-DEPENDENT EXPANSION
CardiALLO
Initial low-dose cohort completed. The company describes a larger randomized plan, not a completed expansion. Form 10-Q, CardiALLO
U.S. PRE-SUBMISSION
Helix catheter
The revised package is for FDA feedback on an investigational delivery system. Company announcement · Device economics
BioCardia deep dive: the full analysis
Why the financing timetable matters, how the cardiovascular programs differ, and what the September financial statements say about the risks. The Merlintrader Research Library collects our dated biotech stock research reports.
01 Three scenarios: who funds the next test?
Bull case — cash arrives before the evidence is due
The favorable case starts with a completed financing or a licensing agreement with enough upfront cash to keep the lead programs moving. A license would be particularly useful if the partner also took responsibility for a defined piece of development or market preparation. The difference between this and a press release about discussions is the transfer of cash or of a bill that BioCardia would otherwise have to pay. A regional license can be attractive on that basis even if the company gives up a share of the future upside. The test is how much work the agreement buys relative to the rights it transfers.
On the product side, a Japanese application that advances into formal review would give that regional strategy something to finance. In the United States, independent authorization of Helix could let partners evaluate a device business without underwriting the efficacy of CardiAMP. Neither development would answer the HF II efficacy question. The strongest version of the favorable case therefore adds steady trial enrollment and a full account of the original HF study, with enough detail to show that the population chosen for the next trial makes sense.
Base case — regulatory progress and financing proceed separately
The middle case is that agency feedback leads to more work, the Japan filing advances, and BioCardia raises enough for selected priorities rather than for everything its platforms could support. An equity bridge might protect the near-term milestones while leaving a later round necessary to carry patients through follow-up. Rights in a second indication and the option to work with more delivery partners could still be worth preserving, but the company would have to sequence those projects behind commitments it has already made.
In this case, a good regulatory headline could coexist with a more demanding capital structure. New shares can extend survival and increase the chance of completing a trial while reducing the fraction of the business attributable to each existing share. Both effects belong in the analysis. The trade-off is easy to miss when the clinical announcement and the financing announcement come weeks apart.
Bear case — additional work arrives before capital does
A request for more device documentation, a delay in Japan, or a slow expansion of HF II might be manageable at a better-funded company. Here those setbacks could arrive while management is negotiating for cash. An investor or partner would then have more leverage over the terms, and clinical sites could face a less predictable timetable. An announced window could slip even if the premise of a given therapy remains worthy of testing.
The most damaging combination would be a financing that only covers immediate obligations plus a regulatory or clinical development that pushes the next decision further out. In that case, a larger share count could arrive without a meaningful reduction in the principal uncertainty. The downside is not confined to a disappointing trial result; the underlying research can remain unresolved if the issuer lacks the resources to finish it. The November 12 Form 10-Q sets out the operating consequences of insufficient funding.
What would falsify this reading
The central reading is that financing limits how much of the cardiovascular opportunity BioCardia can test. A funded development agreement covering a substantial portion of the clinical and regulatory work would weaken that reading, particularly if the payment is nonrefundable and the partner assumes named expenses. Equally, a genuine Helix business with recurring cash receipts could make the next agency milestone less important to the balance sheet. One order or a payment tied to an uncertain event would not produce the same change.
There is an opposite falsification. If an agency required a new clinical package that materially changed the path even with ample funding, the main constraint would become evidence rather than cash. The same shift would occur if a fully funded HF II produced a clear null result in its intended population. Money would no longer be the most useful explanation for the gap between the company’s stated opportunity and its chances of commercialization.
The sequence matters for interpreting intermediate news. A filed application tests the issuer’s ability to prepare a package. Formal review tests the agency’s willingness to evaluate it. Authorization specifies what can be marketed. Payment and adoption determine whether that permission changes the company’s economics. A durable improvement would show up in more than one of those steps, rather than in a revised calendar alone.
02 What BioCardia does: the cells and the delivery equipment
BioCardia develops cardiovascular cell therapies and systems to deliver biological material locally into the heart. CardiAMP uses a patient’s own bone marrow mononuclear cells. A single name covers both a therapy candidate and the system around it: the sponsor has to select an eligible patient, assess the patient’s cells, and deliver the investigational therapy with its catheter. CardiALLO instead uses donor-derived mesenchymal stromal cells. Helix is the catheter platform, the Morph family provides steerable access, and Heart3D is an investigational imaging tool. The interfaces are shared, but a clinician does not use those names interchangeably. Form 10-Q, Overview and program descriptions.
“Ischemic” heart failure refers here to dysfunction related to impaired coronary blood supply and prior damage to heart muscle. Reduced ejection fraction identifies a weakened left ventricle; it is a measure of how much of the blood in that chamber is pumped out with each beat. Low ejection fraction, symptoms and recurrent worsening do not describe exactly the same dimension of disease. A patient may have a severely impaired ventricle but a relatively stable course, while another with a similarly low ejection fraction has frequent episodes requiring escalation of care. A therapy built around persistent risk has to define which group it intends to treat. Heidenreich et al., Circulation 2022.
The relevant comparison is established care, not a patient deprived of treatment. Guidelines for chronic heart failure with reduced ejection fraction include several medication classes that modify outcomes: agents targeting the renin-angiotensin system, evidence-based beta blockers, mineralocorticoid receptor antagonists and sodium-glucose cotransporter 2 inhibitors. Selected patients may also qualify for implanted devices. A catheter-based intervention faces a practical hurdle even after a favorable trial: the added effect must justify a specialized procedure in patients already taking multiple therapies, some of whom have limited reserve. Heidenreich et al., Circulation 2022.
BioCardia describes the CardiAMP hypothesis as improving the microvascular environment in damaged myocardium. The company points to preclinical observations of greater microvascular density and less fibrosis; the strategy does not require claiming that transplanted cells replace all of the damaged muscle. The key clinical question is whether any local biological change is large and sustained enough to alter what happens to patients. A measurement of cardiac structure and a measure of walking ability can illuminate that question from different directions, but neither necessarily moves in parallel with hospitalizations. Form 10-Q, CardiAMP overview · Bolli et al., Cardiovascular Research 2022.
For an autologous therapy, a patient’s condition and the properties of that patient’s cells are separate eligibility questions. Potency screening in CardiAMP was intended to select patients whose own cell samples fit the sponsor’s criteria. That strategy makes biological heterogeneity part of the design rather than leaving all of it to chance after randomization. It also narrows generalizability. Hospitals would need to know how many patients assessed for treatment can actually receive it, how many are excluded for reasons unrelated to heart failure severity, and how reliably assessment and delivery fit into their workflow. Raval et al., American Heart Journal 2018.
The distinction is commercial as well as clinical. A stand-alone catheter could be licensed or supplied for use with multiple partners. A patient-specific system has to be delivered as a reproducible service in addition to meeting a clinical objective. A donor product changes the supply question, but raises its own questions of consistency and immune safety. BioCardia reports one operating segment, so investors cannot infer individual program margins from the consolidated results. The platform may let multiple programs share infrastructure. It does not turn them into a single asset with a single probability of success. Form 10-Q, Note 1 and MD&A.
03 BCDA stock catalysts: what each regulatory step buys
Japan is the nearer potential application for CardiAMP. BioCardia said in its quarterly filing that earlier advice from the Pharmaceuticals and Medical Devices Agency (PMDA) supported submission based on its completed program in ischemic heart failure. The November consultation announcement concerned the materials needed to seek approval. Preparatory advice can reduce the risk of submitting a package that misses known requirements, but it cannot substitute for the benefit-risk determination made during review. In the United States the company describes a different evidentiary path: it says feedback from the FDA’s Center for Biologics Evaluation and Research indicated that the ongoing confirmatory trial may support a Premarket Approval application. Form 10-Q, pp. 11–12 · November 6 consultation announcement.
Shonin is the Japanese marketing approval application in BioCardia’s schedule. The company has engaged a Designated Marketing Authorization Holder to act as its local regulatory representative. The 10-Q describes clinical data preparation, audit work and standardized research datasets for submissions. That matters for a device-therapy system: regulators need to follow clinical outcomes back to the underlying records and assess whether the product and delivery process used in the trials match the proposed commercial system. A filing date is therefore more useful than another statement that discussions continue. It would still leave review, potential questions, and the terms of any authorization ahead. Form 10-Q, CardiAMP regulatory discussion.
The company’s September 23 update had aimed for a fourth-quarter 2026 Japan submission and framed potential market clearance by the fourth quarter of 2027 as conditional on a successful review. The wider submission window in the November results superseded the narrower target. On November 6, Chief Executive Officer Peter Altman said the company targeted first Japanese patients and commercial revenue in 2028. It would take more than a favorable agency decision to reach that stage: the authorization would have to support a usable patient population and the company or its partners would have to fund local operations, supply and market access. September 23 company update · November 6 release · November 12, Exhibit 99.1.
The U.S. paths for CardiAMP and for Helix solve different problems. An FDA determination on the catheter’s intended use would not approve a cell therapy delivered through it. Likewise, acceptance of a pre-submission means a package for feedback is in the relevant process; it is distinct from acceptance of a marketing application. The FDA describes De Novo as a classification path for a novel device without a legally marketed predicate when general controls, or general and special controls, can provide reasonable assurance of safety and effectiveness. In that context, the intended use and the controls matter more than the number of prior uses mentioned in a press release. FDA De Novo classification guidance and process · October 19 Helix announcement.
In the November results, the company expected a full Helix De Novo submission in the first quarter of 2027 and described possible authorization in mid-2027 if the FDA met the 150-review-day goal cited by BioCardia. A regulatory review goal is not a calendar-day commitment or an approval outcome. It does not capture every preparation interval, possible additional-information request, or issue that could change scope or timing. An actual application would pin down which device and proposed label the agency is being asked to review. November 12, Exhibit 99.1, Helix section · FDA review process.
Heart3D has its own planned submission and a prospective partner study. On these paths, a useful update should name the submission or study that actually occurred. It should identify the intended use, the party responsible and, where appropriate, whether a collaboration includes payment. Using the same catheter or imaging system in a prospective study can build adoption evidence, but does not in itself create booked sales. November 12, Exhibit 99.1, anticipated milestones.
04 CardiAMP HF I and HF II: a new trial, not a new reading of the old endpoint
The original CardiAMP HF trial began with a small open-label roll-in. The registry lists 125 participants overall, while BioCardia reports 115 enrolled in the randomized cohort at 28 U.S. centers. The 10-person roll-in accounts for the difference. Observing how a procedure fits into clinical care and following early patients serves a different purpose from estimating an effect against a control. Findings from those first patients can be useful for feasibility even when the randomized comparison produces a different conclusion. ClinicalTrials.gov, NCT02438306 · Form 10-Q, pp. 11–12.
The registered primary endpoint for HF I was a three-tier composite assessed at 12 months. It compared patients on death first, then nonfatal major adverse cardiac and cerebrovascular events, then change in six-minute walk distance for the remaining comparisons. The Raval et al. design article, American Heart Journal 2018, described the central role of walking distance and how major events were to be taken into account. The later registry record is the more direct source for the hierarchy as analyzed. The structure avoids treating a modest change in walking distance as more important than death, while allowing information about functional status to contribute when higher-order outcomes do not distinguish pairs.
The randomized cohort missed its primary efficacy outcome. BioCardia reports that a subgroup with elevated NT-proBNP, a marker of cardiac stress, showed favorable findings, including a key secondary outcome in that subgroup. The company also discussed imaging at a subsequent scientific meeting. Those signals support a hypothesis about where to look next; the main trial result remains negative on its primary endpoint. A subgroup analysis is easier to interpret when readers know the cutoff, the number of patients and events on each side, how the analysis was specified, and how many other analyses competed for attention. A peer-reviewed manuscript would make those details easier to assess but would not be a second independent trial. Form 10-Q, pp. 11–12.
Safety requires a similarly exact denominator. In the 10-patient roll-in, Raval et al., International Journal of Cardiology 2021, reported no serious adverse events related to marrow aspiration or cell delivery. In the randomized cohort, BioCardia reported three treatment-emergent major adverse cardiac events that resolved without sequelae. The two reports concern different populations and definitions. A patient with underlying ischemic disease can have serious events irrespective of treatment, which is one reason timing, attribution and the comparator matter. Form 10-Q, completed CardiAMP HF trial.
HF II prospectively selects a higher-risk group. BioCardia describes patients with ischemic heart failure, reduced ejection fraction and NT-proBNP above 500 pg/mL despite guideline-directed care. It plans up to 250 patients and up to 40 U.S. centers. The trial compares the CardiAMP system with a sham control: diagnostic catheterization of the left ventricle without administration of the autologous cells. Masking participants and outcome assessors is particularly important when a patient questionnaire contributes to efficacy. The release counted four recruiting sites and seven being onboarded; neither number is a count of randomized patients. ClinicalTrials.gov, NCT06258447 · November 12 results release.
| Rank | HF II primary efficacy hierarchy | Implication |
|---|---|---|
| First | All-cause death and equivalents including heart transplant or placement of a left ventricular assist device, ordered by time to event. | The most serious outcomes take precedence over the lower tiers. |
| Second | Nonfatal events including heart failure hospitalization or worsening heart failure, stroke or myocardial infarction, with specified early procedure-related exclusions. | A nonfatal event can decide a comparison when the first tier does not. The primary efficacy exclusions make separate safety reporting important. |
| Third | Change in Minnesota Living with Heart Failure Questionnaire score. | Quality of life replaces the walk test at this tier; walking distance remains a secondary measure. |
The registry specifies 12 to 24 months of follow-up at endpoint analysis. In a ranked composite, which component drives the result can be as informative as the overall statistic. A result driven by the questionnaire might matter to patients, but makes a different claim from one supported by fewer hospitalizations or deaths. Readers should look for the component results, an effect estimate with its uncertainty, missing data and follow-up by arm. More events in a selected high-risk group can make the study informative; they can also expose procedure-related vulnerabilities that would be difficult to detect in an early cohort. HF II registered outcome measures.
The study record was updated in February 2026 and lists April 2027 as estimated primary completion and April 2029 as estimated overall completion. The estimates are not promised disclosure dates. Site onboarding occurs before a site can contribute a patient, and follow-up begins after treatment or the control procedure, not when a center is announced. The combination of a clinical follow-up interval and a much shorter corporate runway makes enrollment pace and financing relevant to the quality and timing of the eventual evidence. ClinicalTrials.gov, study dates · Form 10-Q, Future Funding Requirements.
05 Refractory angina, CardiALLO and evidence from related therapies
CardiAMP’s chronic myocardial ischemia program addresses patients with refractory angina who lack suitable conventional revascularization options. Symptoms can limit activity even when the clinical question is not the same as in advanced heart failure. The registered primary efficacy measure is change in total treadmill exercise time at six months using a modified Bruce protocol. The registry lists the study as active, not recruiting, with an estimated enrollment of up to 343; that figure describes the study design, not the number represented in the reported open-label cohort. ClinicalTrials.gov, NCT03455725 · Form 10-Q, chronic myocardial ischemia section.
At EuroPCR in May 2026, the company reported that the open-label cohort improved by an average of 179 seconds on exercise testing, with the improvement persisting through two years, and that angina episodes fell by an average of 82% at six months. It reported no treatment-emergent major adverse cardiac events in that cohort. A comparison with patients’ own starting values can show whether an observation is worth pursuing. It cannot separate the intervention from expectation, changes in other care, or variability in how symptoms and exercise tolerance are measured. The magnitude belongs with the design and context, not with the estimated size of the larger trial. BioCardia’s May 21 EuroPCR results announcement.
Prior randomized work in angina gives this question a useful reference point without supplying an answer for CardiAMP. In a 167-patient study, the lower-dose group receiving mobilized autologous CD34-positive cells had fewer weekly angina episodes than placebo at six and twelve months; results in the higher-dose group did not reach significance. The same paper described cardiac enzyme elevations associated with its cell-mobilization and collection process. Those findings belong to that study’s selected cell product and collection method. The different composition and collection procedures in CardiAMP limit direct transfer of either the efficacy magnitude or the safety rate. Losordo et al., Circulation Research 2011.
A pooled analysis of randomized CD34-positive cell studies reported improved treadmill time at three and six months; the confidence interval for the twelve-month estimate included no difference. The authors also reported lower angina frequency at all three assessed time points. The contrast is informative: a signal can differ by metric and visit even in a pooled dataset. A controlled CardiAMP result would need to show what happened on its own primary outcome, with enough follow-up to assess the persistence of any benefit. Henry et al., European Heart Journal 2018.
CardiALLO uses donor-derived mesenchymal stromal cells and is being studied in ischemic heart failure with an inflammatory component. The quarterly filing says the low-dose cohort was completed and the monitoring board recommended proceeding after reviewing 30-day safety data. The company described no treatment-emergent adverse events, arrhythmias, rejection, or allergic response in that cohort. These are early, sponsor-reported safety observations. The 10-Q also describes a redesigned plan for a 360-patient randomized study, conditional on funding, with a composite involving death, major events and six-minute walk distance. The older registry entry still shows 39 estimated participants, active but not recruiting. The two accounts describe different versions of the development plan. ClinicalTrials.gov, NCT05925608 · Form 10-Q, CardiALLO discussion.
Related heart failure trials explain why the distinction between a reassuring safety observation and efficacy is consequential. In TAC-HFT, 65 patients were studied across autologous mesenchymal and bone marrow cell cohorts and their placebo controls. There were no treatment-emergent serious adverse events at 30 days, and some functional and structural measures moved, but chamber volume and ejection fraction did not change. Small groups and multiple comparisons limited the strength of the conclusions. Heldman et al., JAMA 2014.
CONCERT-HF compared separate and combined cell populations against placebo in ischemic heart failure. It reported signals in different domains for different cell preparations, without significant between-group differences in measures including ejection fraction and six-minute walking distance. In the much larger DREAM-HF study of a different donor-derived mesenchymal precursor product, the prespecified primary endpoint for recurrent heart failure decompensation or resuscitated symptomatic ventricular arrhythmias was negative. The investigators discussed other signals and inflammation-defined analyses. These studies are context for the evidence hurdle, not indirect efficacy data for CardiALLO. They also explain why a development program based on a selected subgroup must preserve the distinction between its new hypothesis and the original whole-cohort result. Bolli et al., European Journal of Heart Failure 2021 · Perin et al., Journal of the American College of Cardiology 2023.
06 BioCardia earnings: a larger quarterly loss and a smaller nine-month loss
The September 2026 quarter has the financial profile of a development business. The income statement shows no revenue for the quarter or for the nine months, just as it shows none in the comparable 2025 periods. BioCardia notes modest historical sales from products already cleared for certain uses. Those sales and possible development services are separate from revenue on the investigational therapies, and neither provides a basis for assigning revenue to a planned application. The key earnings comparison is how much the issuer spent, on what, and what it still needs to fund. Form 10-Q, statement of operations and business description.
| USD thousands | Q3 2026 | Q3 2025 | 9M 2026 | 9M 2025 |
|---|---|---|---|---|
| Research and development | 1,235 | 936 | 3,363 | 3,834 |
| Selling, general and administrative | 600 | 552 | 2,361 | 2,431 |
| Operating loss | (1,835) | (1,488) | (5,724) | (6,265) |
| Other income, net | 18 | 5 | 35 | 21 |
| Net loss | (1,817) | (1,483) | (5,689) | (6,244) |
Research and development drove the quarterly increase. BioCardia attributed it primarily to a higher bonus accrual together with regulatory work in Japan and enrollment in HF II. The nine-month comparison reflects reduced development expense after completion of the original CardiAMP heart failure study, partly offset by the new work. A completed trial changes which expenses are incurred; it does not imply spending will stay at the lower interim level. The company uses employees and infrastructure across programs and says it has not historically allocated its resources to individual projects. Exact costs for producing a specific filing or finishing HF II cannot be inferred from the total. Form 10-Q, Results of Operations.
The operating and net losses reconcile through small amounts of net other income. The quarterly net loss per share was $0.12 against $0.24 in the September 2025 quarter, although the dollar loss increased. Quarterly basic and diluted weighted-average shares were 15.14 million and 6.28 million, respectively, for the two comparison periods. The per-share improvement followed the much larger denominator; the operating statement shows no corresponding improvement in the quarterly spending gap. Comparing only loss per share would reverse the impression given by the aggregate result. Form 10-Q, statement of operations and Note 8.
The cash-flow comparison tells a third story. The release puts both September quarters at approximately $1.7 million in operating cash use. Nine-month cash use increased even though the equivalent net loss fell; management pointed principally to the timing of supplier payments. This is the kind of split that matters when a company is running close to its financing needs. A clinical accrual appears when an obligation is recognized, while the cash bill may come in another period. Compensation delivered in equity can reduce cash use while shifting part of the cost to share count. Neither a modestly better interim net loss nor a flat rounded quarterly cash figure is enough to project the next budget. November 12 results release, Financial Results · Form 10-Q, cash flows and MD&A.
07 Cash and burn: why the balance moved less than operating outflows
The audited year-end 2025 cash balance was $2.496 million. By September 30, 2026 cash and equivalents were $2.224 million. The September balance sheet does not show a separate pool of marketable securities or a separate restricted-cash line. Taken alone, the small decline could suggest that the cash balance was stable. The cash-flow statement instead shows that external financing offset most of the outflow. With the old ATM no longer available under its existing supplement, the same comparison is unlikely to explain the next period in the same way unless a new source replaces it. Form 10-Q, balance sheet, cash flows and liquidity discussion.
| Nine months through September 30, 2026 | USD thousands | What it represents |
|---|---|---|
| Opening cash and equivalents | 2,496 | December 31, 2025 balance |
| Operating activities | (5,114) | Cash used in the business; $4.939 million used in the comparable 2025 period |
| Investing activities | (4) | Property and equipment purchases |
| Financing activities | 4,846 | Stock sale and warrant proceeds, net of issuance costs and equity-award withholding payments |
| Closing cash and equivalents | 2,224 | September balance; decline of $272,000 over nine months |
Merlintrader calculation: $5.114 million divided by nine is about $568,000 per month, so the September cash balance represented about 3.9 months of that historical average operating cash use. This back-of-the-envelope comparison starts at the balance sheet date. It is neither a November cash balance nor a forecast of a day on which cash runs out. Clinical payments, regulatory work, staffing and supplier terms can change monthly use, and the historical average does not capture all financing or investing flows. Management’s assessment is the more relevant account of its current plan. Form 10-Q, statement of cash flows and Future Funding Requirements.
The filed assessment says the September cash and equivalents were insufficient to fund planned expenditures and meet obligations beyond January 2027 without additional funding. Management identified substantial doubt about the company’s ability to continue as a going concern within a year of issuing the financial statements. The cash date and the horizon for that accounting judgment are different. “Runway into 2027” in the earnings release is a description of the same immediate funding problem, not an indication that the company can pay for the full 2027 plan. Form 10-Q, liquidity and going concern · November 12 results release.
Working capital gives another view of the near-term margin. At September 30, current assets of $2.332 million covered current liabilities of $2.092 million, a difference of $240,000 (Merlintrader calculation). Working capital is not a second pot of money to add to bank balances. It includes cash and other near-term assets, net of obligations, and it does not time individual receipts or payments. A company that has cash today can still have a thin margin against commitments. Conversely, treating the full amount of all year-ahead obligations as if it were due immediately would understate the flexibility of the business. Form 10-Q, balance sheet.
Practical signs of relief would include proceeds actually received and a stated use of funds that covers more than immediate bills. Other indicators are an extension under an updated spending plan or a partner taking over costs in a defined program. An agreement that includes mostly contingent milestones may be strategically important without covering the next payroll or site payment. The most useful financing disclosures would therefore give the net cash, the date received, the associated rights and restrictions, and the remaining work that cash is expected to support.
08 Helix, Morph and Heart3D: what can become a business on its own?
The device strategy gives BioCardia a possible economic route that is narrower than approving a therapy. Helix is designed to let physicians deliver therapeutic or diagnostic agents into the heart muscle from within the ventricle. That intended use creates a potential role in other developers’ studies, even if those studies have nothing to do with CardiAMP. BioCardia presented marketing authorization as a way to expand partnerships. In the 10-Q, the company says the FDA preferred approval alongside CardiAMP but identified a possible independent De Novo path for the catheter. The meaningful evidence will be the intended use in a final FDA decision, the commercial rights held by BioCardia, and what independent partners actually commit to do. A platform’s theoretical compatibility with several types of agents is broader than any given authorization. October 19 Helix release · Form 10-Q, Helix section.
The Morph family is a distinct line. BioCardia reports clearances for transseptal procedures under the AVANCE name and for certain vascular uses under the Morph DNA name. Those permissions do not cover administering CardiAMP. Devices used in a common procedure can sit at very different regulatory stages; a legally marketed introducer does not imply that the catheter, imaging software or biological material used with it is authorized for the proposed system. Nor does that history imply a sales run rate. The absence of a revenue line in the September figures is a useful constraint on assigning current financial value to the published clearances. Form 10-Q, Morph description and statement of operations.
Heart3D adds a software layer. The concept overlays a three-dimensional heart model built from pre-procedure imaging on live two-dimensional X-ray guidance. BioCardia describes development with CART-Tech and reports worldwide exclusive licenses and distribution rights for biotherapeutic delivery, plus U.S. rights for cardiac biopsy. Technical demonstrations cited in the filing are distinct from clinical validation, and an application for one use does not automatically allow another. A software-led commercial case would need evidence that hospitals can integrate it into existing systems, that operators can use it reproducibly, and that the resulting workflow is worth paying for. Form 10-Q, Heart3D section · November 12 business highlights.
One possible first market is development work with partners rather than broad clinical sales. That distinction determines which metrics matter. An instrument or service used in a partner study may generate a fee or cost reimbursement; a deployment across hospitals would bring a different revenue, support, and regulatory profile. Signing a collaboration, receiving cash, and later sharing revenues from a successful partner product are three separate events. Terms that specify minimum purchases, exclusivity or cost sharing would make the commercial claim more measurable than a list of potential uses.
09 Debt, lease commitments and flexibility under stress
The September balance sheet shows no separate borrowing or convertible-debt line. The company has historically used convertible debt, but that history is different from an outstanding instrument at the balance-sheet date. It did report $2.236 million in liabilities, including $565,000 in operating lease liabilities. Accounts payable and accruals are due in the ordinary course and are not interchangeable with either a financing facility or a debt covenant. Clinical cost accruals also give an incomplete view of work to come; they represent recognized amounts, not the entire remaining cost of a trial. Form 10-Q, balance sheet and Notes 1, 4 and 5.
On September 3, 2026, BioCardia extended its laboratory and office lease to January 31, 2028. The amendment increased the recognized right-of-use asset and lease liability by $390,000. That change reflects the value of additional lease payments, rather than cash borrowed for research. The company reported $611,000 of undiscounted future lease payments at September 30: $128,000 for the rest of 2026, $446,000 for 2027 and $37,000 for 2028. Deducting $46,000 of imputed interest gives $565,000 (Merlintrader calculation), of which $421,000 was current. Form 10-Q, Note 4 and balance sheet · September 3 lease amendment.
The lease has a conditional extension option; the filing says it contains no material restrictive covenants or material residual guarantees. The company reports no finance leases and no off-balance-sheet arrangements under the SEC definition. The quarter’s legal proceedings section reported no material pending proceedings. Future debt, if obtained, could change this picture through restrictions, interest service or conversion features. The key question then would be whether BioCardia had added a reliable source of liquidity or traded some of its ability to fund the next stage for short-term cash. Form 10-Q, Note 4, MD&A and Part II.
10 BCDA share dilution: the funding already raised and the gap ahead
Shares outstanding increased from 10,755,647 at December 31, 2025 to 15,138,782 at September 30, 2026. The cover of the 10-Q uses the same latter count as of November 11. The reconciliation is 4,189,055 ATM shares plus 31,000 shares from warrant exercises plus 163,080 from restricted stock units, added to the opening count. That is 4,383,135 new shares, or 40.75% of the opening base (Merlintrader calculation). The September quarter itself contributed 154,459 shares from equity awards and no shares from the ATM. An unchanged count from September to the filing-cover date therefore does not describe what happened over the first nine months. Form 10-Q, cover, statement of stockholders’ equity and Note 6.
The old arrangement with H.C. Wainwright & Co. let the company sell shares from time to time through an at-the-market program and carried a 3% commission on gross sales. It brought in $5.309 million gross in the first nine months of 2026. Note 6 reports $238,000 of associated issuance costs for the ATM. The cash-flow statement shows $337,000 of cash issuance costs on stock sales, a separate reporting measure; substituting the Note 6 figure into the cash-flow bridge would not recreate the filed net cash. In that bridge, $5.309 million of stock proceeds less $337,000 of cash issuance costs plus $39,000 from exercises less $165,000 of taxes on net settlement of equity awards equals $4.846 million of financing cash (Merlintrader calculation). Form 10-Q, Note 6 and financing cash flows.
As of September 30 and November 12, the company had no capacity to issue under the existing ATM prospectus supplement. The sales agreement and its historical use do not imply that the prior channel can be turned back on at will. An alternative registration, a negotiated private placement or an arrangement with a strategic partner would each have a different cost and execution risk. A new facility that is usable but undrawn would provide more flexibility than the exhausted supplement, while still leaving a distinction between possible proceeds and funds actually received. Form 10-Q, At-the-Market Offerings and Future Funding Requirements.
Historical deals show how the terms can differ. In September 2025, BioCardia issued 4.8 million common shares with an equal number of warrants in a transaction producing $6.0 million gross and $5.176 million net of disclosed issuance costs. Certain officers and directors participated, together purchasing 734,400 shares with accompanying warrants. Those were securities issued in that financing, not open-market purchases reported in the 2026 insider forms. Separately, a license could bring funding without issuing stock but could transfer part of a product’s economics or control. Evaluating a new deal requires both the immediate cash and the longer-term division of value. Form 10-Q, Note 6, September 2025 financing.
11 Warrants and awards: the overhang is not a cash balance
There were 7,846,514 outstanding and exercisable warrants at September 30, 2026, with a weighted-average exercise price of $1.84. The total reconciles from 7,944,618 at the end of 2025 less 31,000 exercises and 67,104 expirations. The exercises that produced $39,000 in financing cash in 2026 are already reflected in issued shares. Adding those exercises back into the remaining warrant count would double count them. The contract terms differ by series, and a common clinical headline can affect some series differently from others. Form 10-Q, Note 6, warrant activity.
| Series | Shares underlying warrants | Exercise terms |
|---|---|---|
| September 2024 | 2,400,000 | $3.00; maximum expiration September 2029 |
| April 2025 | 406,818 | $1.905 contractual strike; expires by April 2030 or earlier on the specified Japanese approval event |
| June 2025 | 274,696 | $1.95; expires by June 2030 or earlier on the specified Japanese approval event |
| September 2025 | 4,765,000 | $1.25; maximum expiration September 2027 |
The two Japan-linked series are unusual because authorization could shorten their exercise window rather than make the contracts run to their outside dates. Their existence is not a commitment by investors to exercise. Even with a defined exercise price, receipt of cash depends on exercise decisions and terms, including any provisions that constrain a holder’s beneficial ownership. A favorable step in Japan might therefore change both the operating outlook and the capital structure, but it would be wrong to add a hypothetical exercise amount to existing cash. Form 10-Q, Note 6 · November 10 Schedule 13G amendment, warrant blocker.
BioCardia also reported 784,375 options outstanding at September 30, of which 211,596 were exercisable. Across all outstanding options, the weighted-average exercise price was $8.83. The company granted 296,041 restricted stock units during the first nine months, released 163,080 and reported 132,961 forfeited, leaving zero outstanding at September 30. That is why the period-end RSU balance should not be added to the common count as another block of dilution. Equity-based pay keeps part of the expense from requiring current cash, but a settlement can still produce a cash tax payment, as the financing statement shows. Form 10-Q, Notes 7 and 8 and cash flow statement.
The outstanding options and warrants totaled 8,630,889 potential common shares, approximately 57.0% of the issued base (Merlintrader calculation). GAAP excluded those potential shares from diluted loss per share because they would be antidilutive for a loss period. Antidilutive in the income statement is a calculation convention; it does not mean holders could never exercise those rights. The static comparison is useful for scale, but it is not a fully diluted forecast. For a realistic estimate, the relevant variables include exercise conditions, vesting, new securities and whether a financing changes the business before any old instrument can be exercised. Form 10-Q, Notes 6–8.
12 Ownership, short interest and Nasdaq status
A Schedule 13G amendment filed on November 10 lists 1,539,134 shares of beneficial ownership on the September 30 event date. The account consists of 1,271,165 common shares and 267,969 shares that would be issuable from warrants within the applicable ownership limit. The filing explains that the 9.9% figure displayed by EDGAR was rounded down from the 9.99% limit. For the 9.99% calculation, the denominator includes the issuer’s 15,138,782 common shares outstanding as of August 11 plus the 267,969 shares issuable upon the assumed exercise (15,406,751 shares in total). Treating all the holder’s warrants as outstanding common shares, or reading the rounded number as a withdrawal below a reporting threshold, would misstate the document. Schedule 13G/A, November 10, cover and Item 4.
Chief Executive Officer Peter Altman disclosed direct purchases totaling 3,700 common shares on September 3, 23 and 29, 2026: 800, 1,900 and 1,000 shares, respectively. The October 20 Form 4 added purchases of 200 shares on October 15 and 300 on October 16, ending at 385,385 direct common shares in that filing. The transaction code on each of those lines was P. The acquisition indicator in the separate column is not a grant code, and these purchases by a holder are not proceeds to the company. Their scale should be read separately from the much larger cash requirement. September 4 Form 4 · September 23 Form 4 · September 30 Form 4 · October 20 Form 4.
Nasdaq recorded 735,104 shares sold short at the October 30, 2026 settlement, against 678,398 at October 15. The later count was about 4.86% of BioCardia’s November 11 common shares (Merlintrader calculation); that is a comparison with total outstanding, not with public float. Nasdaq reports an average daily share volume of 116,810 for the October 30 calculation, giving about 6.29 days to cover, versus about 5.05 at October 15. Days to cover is an arithmetic relationship to a volume measure, not a deadline to close positions. Short interest measures positions at settlement dates, not the number of shares marked short in one trading session. Nasdaq short-interest history · Form 10-Q cover.
In the 14 completed sessions from November 2 through 19, Nasdaq’s historical table shows a median of about 80,834 shares and a mean of about 103,018 (Merlintrader calculations), with sessions ranging from 22,989 to 296,616 shares. This window is illustrative rather than the denominator of the settlement statistic just cited. It shows why daily capacity to absorb orders deserves separate attention from the nominal size of the company or the size of a proposed financing. Historically low volume on some of these sessions increases the risk of thin trading if a material update arrives. Nasdaq historical trading data.
On November 20, 2026, Nasdaq notified BioCardia that it fell short of the Nasdaq Capital Market’s $2.5 million minimum stockholders’ equity requirement under Rule 5550(b)(1). BioCardia reported $835,000 in stockholders’ equity as of September 30, down from $2.700 million at June 30. The September balance was $1.665 million below the requirement (Merlintrader calculation). At December 31, 2025, stockholders’ equity was $895,000, and at March 31, 2026, the company had a $1.066 million stockholders’ deficit. Form 10-Q, statements of stockholders’ equity · Nasdaq Rule 5550 · November 20 Form 8-K. Nasdaq set January 4, 2027, as the deadline for a compliance plan, and BioCardia says it intends to submit one. If Nasdaq accepts the plan, it may grant up to 180 calendar days from November 20, 2026, for the company to demonstrate compliance. If Nasdaq rejects the plan, the company may request a hearing. BioCardia reported that the notice had no immediate effect on listing or trading and that its common stock would continue trading on the Nasdaq Capital Market. November 20 Form 8-K. The equity notice concerns a separate rule from the August minimum bid-price deficiency. BioCardia reported on September 21 that Nasdaq had closed the earlier matter after the required compliance period. September 21 Form 8-K · November 20 Form 8-K.
13 What matters next: the cost and value of the next answer
BioCardia has more than one way to make progress, but each path needs its own evidence. A Japanese filing would test regulatory execution. A Helix decision would define a device opportunity. Trial enrollment and eventual randomized outcomes would test the therapy. A financing would change how many of those steps the business could support, not the scientific result of any of them. The events belong on one calendar because they draw on the same company’s resources, not because one positive result automatically carries over to the others.
Commercial scenarios also depend on how much of any opportunity the issuer retains. Geographically limited rights, use restrictions or payments tied to later milestones could make a large headline value less helpful than a modest upfront check. The same logic applies to a device partnership that provides access but leaves BioCardia paying most of the development costs. New disclosures that tie the scope of work, cash timing and rights together would provide a stronger basis for assessing the business than extrapolating a theoretical population into sales.
The key question for the coming months is whether the company can finance evidence without giving up so many rights or issuing so many securities that the result changes what existing holders own. The September balance sheet explains why that question comes before distant launch scenarios. The case becomes more constructive with a funded clinical path and clearer agency decisions. It remains fragile if the next milestone turns mainly into another timetable while unfunded obligations come closer. Form 10-Q, Future Funding Requirements · November 12 milestones.
Merlintrader Health Score · $BCDA
1.6out of 5
Assessed November 20, 2026. Merlintrader calculation: 1.0 × 30% + 2.5 × 30% + 1.0 × 20% + 1.5 × 10% + 2.0 × 10% = 0.30 + 0.75 + 0.20 + 0.15 + 0.20 = 1.60, or 1.6 out of 5. The score describes financial and operational robustness over twelve to eighteen months. It is not an investment recommendation.
Red flags
- The company’s filed cash horizon is shorter than the confirmatory trial’s follow-up requirements.
- Japan’s completed consultation leaves the submission, review and marketing decision ahead.
- Evidence in HF I’s elevated-biomarker subgroup cannot replace the missed primary outcome in the randomized cohort.
- After the ATM ran out of issuance capacity under its existing supplement, the next financing could change the ownership denominator or transfer rights.
- BioCardia has until January 4, 2027 to submit a plan addressing its Nasdaq stockholders’ equity deficiency. November 20 Form 8-K.
BCDA Stock FAQ: BioCardia Questions Answered
What are BioCardia’s next regulatory catalysts after PMDA consultation?
As of November 20, 2026, BioCardia’s next announced windows were fourth-quarter Helix feedback and a Japanese CardiAMP submission in the fourth quarter of 2026 or first quarter of 2027. The company had not given a fixed day for either. FDA feedback on the catheter and filing an application in Japan are different steps for different products. November 12 company milestones.
Did the FDA approve BioCardia’s Helix catheter?
No. As of November 20, 2026, BioCardia had announced acceptance of a revised pre-submission for feedback, not a marketing authorization. Its November release targeted the full De Novo request for the first quarter of 2027. October 19 release · November 12 update.
How much cash does BioCardia have, and is there a going-concern warning?
BioCardia reported $2.224 million in cash and equivalents at September 30, 2026 and disclosed substantial doubt about its ability to continue as a going concern. The November 12 filing said the September cash would not support its planned spending and obligations beyond January 2027 without additional funding. Form 10-Q, liquidity and going concern.
How many BCDA shares are outstanding, and could BioCardia raise more capital?
The November 12, 2026 Form 10-Q reports 15,138,782 shares outstanding on November 11. BioCardia says it needs additional funding and had no available issuance capacity under its existing ATM prospectus supplement on November 12. A new financing, warrant exercise or equity award settlement can still change the share count. Form 10-Q cover and liquidity discussion.
When did BioCardia report its third-quarter results?
BioCardia issued its third-quarter results and filed the 10-Q on November 12, 2026, for the period ended September 30. Its quarterly net loss was $1.817 million. Earnings release · Form 10-Q.
What does BioCardia do?
In its November 12, 2026 filing, BioCardia described a clinical-stage business developing cell therapies and local delivery systems for cardiovascular disease, alongside a pulmonary research program. CardiAMP uses patients’ own cells; CardiALLO is donor-derived. Helix is an investigational delivery catheter rather than a therapy. Form 10-Q, Overview.
What did Nasdaq decide about BioCardia’s listing?
On November 20, 2026, Nasdaq notified BioCardia that its stockholders’ equity was below the minimum requirement for continued listing. The notice left trading and listing in place at the time. BioCardia has until January 4, 2027, to submit a compliance plan. The earlier bid-price matter was closed in September under a separate rule. November 20 Form 8-K · September 21 Form 8-K.
How does BioCardia’s CardiAMP HF II differ from the first trial?
As described in the November 12, 2026 filing, HF II recruits patients with elevated NT-proBNP, a group suggested by the first trial’s subgroup findings. In its registered primary hierarchy, a quality-of-life measure replaces change in six-minute walking distance at the third tier. HF II is recruiting; the first trial did not meet its primary efficacy endpoint. HF II study record · Form 10-Q.
Sources
Filings, regulators and trial records
- BioCardia Form 8-K · November 20, 2026 · Nasdaq stockholders’ equity deficiency
- BioCardia Form 10-Q · September 30 quarter · filed November 12, 2026
- Third-quarter results · November 12, 2026 · Exhibit 99.1
- November 12, 2026 Form 8-K · Item 2.02
- November 12, 2026 · BioCardia investor relations release (program updates; see SEC filings for financial figures)
- Japan PMDA consultation completed · November 6, 2026 · Exhibit 99.1
- Helix revised pre-submission acceptance · October 19, 2026 · Exhibit 99.1
- BioCardia · September 23, 2026 · Japan and Helix timelines
- BioCardia · May 21, 2026 · EuroPCR open-label angina cohort
- BioCardia · September 3, 2026 · lease amendment
- BioCardia · September 21, 2026 · closure of Nasdaq bid-price matter
- Nasdaq Capital Market · Rule 5550 continued listing requirements
- Nasdaq · BCDA short interest
- Nasdaq · BCDA historical trading volume
- November 10, 2026 · Schedule 13G/A · September 30 ownership
- September 4, 2026 · Form 4 · Peter Altman
- September 23, 2026 · Form 4 · Peter Altman
- September 30, 2026 · Form 4 · Peter Altman
- October 20, 2026 · Form 4 · Peter Altman
- FDA · De Novo classification requests
- ClinicalTrials.gov · CardiAMP HF I · NCT02438306
- ClinicalTrials.gov · CardiAMP HF II · NCT06258447
- ClinicalTrials.gov · CardiAMP chronic myocardial ischemia · NCT03455725
- ClinicalTrials.gov · CardiALLO · NCT05925608
Peer-reviewed clinical literature
- Heidenreich et al., Circulation 2022 · heart failure guideline · DOI 10.1161/cir.0000000000001063
- Bolli et al., Cardiovascular Research 2022 · cell therapy in heart failure · DOI 10.1093/cvr/cvab135
- Raval et al., American Heart Journal 2018 · CardiAMP HF design · DOI 10.1016/j.ahj.2018.03.016
- Raval et al., International Journal of Cardiology 2021 · CardiAMP HF open-label roll-in · DOI 10.1016/j.ijcard.2020.10.043
- Losordo et al., Circulation Research 2011 · randomized CD34-positive cell therapy in angina · DOI 10.1161/circresaha.111.245993
- Henry et al., European Heart Journal 2018 · pooled CD34-positive cell trials · DOI 10.1093/eurheartj/ehx764
- Heldman et al., JAMA 2014 · TAC-HFT · DOI 10.1001/jama.2013.282909
- Bolli et al., European Journal of Heart Failure 2021 · CONCERT-HF · DOI 10.1002/ejhf.2178
- Perin et al., Journal of the American College of Cardiology 2023 · DREAM-HF · DOI 10.1016/j.jacc.2022.11.061
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $BCDA or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
BioCardia faces clinical failure, catheter-related safety risks, regulatory delays, uncertain reimbursement, financing and dilution risk, and possible loss of Nasdaq listing. Investors can lose their entire investment. Read the primary sources, conduct your own research and consult a licensed adviser before making investment decisions. Disclaimer.



